Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Carbocyclic Nucleoside. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel synthetic route for Entecavir intermediates avoiding guanine ring-opening. High purity, scalable process for antiviral API manufacturing.
Patent CN102603652A reveals a mild three-step synthesis for 5-formylpyrimidine carbocyclic nucleosides, offering a reliable route for antiviral intermediate manufacturing.
Patent CN109761984B details a novel ruthenium-catalyzed asymmetric hydrogen transfer method for synthesizing chiral purine nucleosides with high enantioselectivity and mild conditions.
Patent CN107698590B details a novel asymmetric [3+2] cyclization for chiral carbocyclic purine nucleosides, offering high yields and enantioselectivity for reliable pharmaceutical intermediate supply.
Patent CN108558882B reveals a novel [3+2] cycloaddition route for chiral nucleosides, offering high enantioselectivity and streamlined manufacturing for pharmaceutical intermediates.
Patent CN109761984B reveals a novel asymmetric hydrogen transfer method for high-purity chiral purine nucleosides, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN110590781B reveals a novel Pd-catalyzed asymmetric allylic amination route for high-purity antiviral intermediates, offering significant cost reduction and scalable manufacturing capabilities.
Patent CN108912123B enables high-purity chiral nucleosides through asymmetric catalysis with simplified process and reduced manufacturing costs.
Patent CN109761984A enables high-purity chiral carbocyclic purine nucleosides synthesis via asymmetric hydrogen transfer. This method eliminates high-pressure hydrogenation systems while achieving up to 99% enantioselectivity and ensuring reliable pharmaceutical supply chains.
Patent CN108314655A enables high-purity chiral nucleoside synthesis with 99% ee, reducing API manufacturing costs and ensuring reliable supply chain for pharmaceutical intermediates.
Patent CN109761984B enables high-purity API intermediates through asymmetric hydrogen transfer with enhanced supply chain reliability and reduced manufacturing costs.